Librium
(chlordiazepoxide)Phase 3Small molecule
Chlordiazepoxide is a medication that reduces anxiety and helps control agitation caused by alcohol withdrawal. It works by calming excessive electrical activity in the brain to help you feel more relaxed and stable.[1] Librium is currently being investigated across 1 indication[3], with its most advanced program in Phase 3.[1]
Librium is one of 23 small molecule programs targeting Alcohol Withdrawal. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
22
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
26 competitors in Alcohol Withdrawal
#DrugCompanyPhaseTrials
1Lioresal
NovartisApproved
Depakote
TevaApproved
Xyrem
Jazz PharmaceuticalsApproved
Ativan
BBausch Health Americas, Inc.
Approved
Minipress
PfizerApproved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Ketalar
AAultman Health Foundation
Approved
Pitocin
RRetrophin
Approved
Epsom Salt
FFresenius Kabi Oncology Ltd.
Approved
Keppra
UCBPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
LIBRIUM
NDA NDA012249
Jan 1, 1982
LIBRIUM
NDA NDA012301
Sep 12, 1983
LIBRELEASE
NDA NDA017813
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for chlordiazepoxide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBausch Health Americas, Inc.